Close Menu

NEW YORK (GenomeWeb) – Luminex said on Sunday that it expects to report fourth quarter revenues of around $78 million, up 8 percent from the prior-year quarter, and full-year 2017 revenues of more than $306 million, an increase of 13 percent from the prior year.

The firm said that it expects molecular diagnostics product revenues to rise 12 percent year-over-year to about $44 million. Its MDx sample-to-answer portfolio is expected to grow 33 percent over the prior-year quarter and generate $13 million in Q4.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Financial Times reports the US bolstering its ability to track SARS-CoV-2 alterations.

The New York Times reports that Cedars-Sinai researchers have uncovered a new strain of SARS-CoV-2 in Southern California.

In Nucleic Acids Research this week: pan-cancer atlas focus on miRNA biogenesis mutations, methylation analysis of pig skeletal muscles, and more.

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.